Sino Biopharmaceutical announced drug development and sales pacts with two UK pharma companies on Wednesday, AstraZeneca and GSK, for separate respiratory partnerships
Sino Biopharmaceutical announced drug development and sales pacts with two UK pharma companies on Wednesday.
One will see the Hong Kong biotech
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Sino Biopharmaceutical fecha acordo bilionário com a AstraZeneca e expande parceria com a GSK
AstraZeneca, GSK intensify China ties with Sino Biopharm deals
Fierce Pharma Asia—More AZ China deals; Kailera, Hengrui’s oral GLP-1 data; Scrutiny of Chinese trials
GSK, Hansoh ADC extends survival in lung cancer study
Dow Jones Top Company Headlines at 3 AM ET: Sino Biopharm Strikes Drug Licensing Deal With AstraZeneca, Deepens GSK Partnership | White ...
As duas parcerias ocorrem em meio a uma onda de acordos de licenciamento e associações entre companhias biofarmacêuticas globais…
The U.K. drugmakers added to a series of recent tie-ups with Chinese counterparts amid broader scrutiny of such transactions in…
AstraZeneca strikes another deal with CSPC, worth up to $1.7B, to develop siRNA candidates for renal diseases — months after…
The marketing deal is the latest in a series of recent pacts between GSK and China-based drug companies, and could speed access…
SAN DIEGO — Korean biotechnology firms have advanced their partnerships with AstraZeneca, bolstering efforts toward open…
In the two weeks before and after Independence Day in the U.S., AstraZeneca signed potential billion-dollar licensing deals with…
